Mesoblast’s rexlemestrocel-L was granted FDA orphan designation as a treatment of Hypoplastic Left Heart Syndrome, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MESO:
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
- Biotech Alert: Searches spiking for these stocks today
- United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
- Mesoblast receives RPD designation for Revascor from FDA
- Mesoblast trading halted, news pending